The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Cavalu S.; Saber S.; Amer A.E.; Hamad R.S.; Abdel-Reheim M.A.; Elmorsy E.A.; Abdelhamid A.M.

Journal: FASEB Journal

Publisher: John Wiley and Sons Inc

Publication Date: 2024

Volume / Issue: Volume 38 / Issue 13

Article No.: e23813

ISSN: 8926638

DOI: 10.1096/fj.202400725RR

Scopus: View on Scopus

PubMed: 38976162

Document Type: Review

Access: All Open Access; Hybrid Gold Open Access


Authors and Affiliations

Cavalu S., Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania; Saber S., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt; Amer A.E., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt; Hamad R.S., Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia, Central Laboratory, Theodor Bilharz Research Institute, Giza, Egypt; Abdel-Reheim M.A., Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra, Saudi Arabia, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt; Elmorsy E.A., Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, Saudi Arabia, Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Abdelhamid A.M., Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt


Abstract

Beta-blockers are commonly used medications that antagonize β-adrenoceptors, reducing sympathetic nervous system activity. Emerging evidence suggests that beta-blockers may also have anticancer effects and help overcome drug resistance in cancer treatment. This review summarizes the contribution of different isoforms of beta-adrenoceptors in cancer progression, the current preclinical and clinical data on associations between beta-blockers use and cancer outcomes, as well as their ability to enhance responses to chemotherapy and other standard therapies. We discuss proposed mechanisms, including effects on angiogenesis, metastasis, cancer stem cells, and apoptotic pathways. Overall, results from epidemiological studies and small clinical trials largely indicate the beneficial effects of beta-blockers on cancer progression and drug resistance. However, larger randomized controlled trials are needed to firmly establish their clinical efficacy and optimal utilization as adjuvant agents in cancer therapy. © 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.


Keywords

angiogenesis; apoptosis; beta-blockers; cancer; drug resistance; metastasis; Adrenergic beta-Antagonists; Animals; Antineoplastic Agents; Cardiovascular Diseases; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Receptors, Adrenergic, beta; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; antineoplastic agent; beta adrenergic receptor; cancer growth; cancer resistance; cancer stem cell; cardiovascular disease; chemosensitization; clinical study; drug effect; drug mechanism; drug use; human; nonhuman; outcome assessment; preclinical study; Review; animal; disease exacerbation; drug therapy; metabolism; neoplasm; pathology


Citation Information

Scopus Citations: 37


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region